- Home
- ACCD vs ACIU Comparison
ACCD vs ACIU Comparison
Compare ACCD & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCD
- ACIU
- Stock Information
- Founded
- ACCD 2007
- ACIU 2003
- Country
- ACCD United States
- ACIU Switzerland
- Employees
- ACCD N/A
- ACIU N/A
- Industry
- ACCD Business Services
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- ACCD Consumer Discretionary
- ACIU Health Care
- Exchange
- ACCD Nasdaq
- ACIU Nasdaq
- Market Cap
- ACCD 281.1M
- ACIU 305.7M
- IPO Year
- ACCD 2020
- ACIU 2016
- Fundamental
- Price
- ACCD $3.70
- ACIU $3.38
- Analyst Decision
- ACCD Buy
- ACIU Strong Buy
- Analyst Count
- ACCD 12
- ACIU 2
- Target Price
- ACCD $9.04
- ACIU $12.00
- AVG Volume (30 Days)
- ACCD 1.3M
- ACIU 132.6K
- Earning Date
- ACCD 01-06-2025
- ACIU 11-05-2024
- Dividend Yield
- ACCD N/A
- ACIU N/A
- EPS Growth
- ACCD N/A
- ACIU N/A
- EPS
- ACCD N/A
- ACIU N/A
- Revenue
- ACCD $441,028,000.00
- ACIU $48,505,404.00
- Revenue This Year
- ACCD $15.56
- ACIU N/A
- Revenue Next Year
- ACCD $11.76
- ACIU $938.44
- P/E Ratio
- ACCD N/A
- ACIU N/A
- Revenue Growth
- ACCD 16.04
- ACIU 4097200.00
- 52 Week Low
- ACCD $3.08
- ACIU $2.25
- 52 Week High
- ACCD $15.36
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- ACCD 57.22
- ACIU 55.80
- Support Level
- ACCD $3.30
- ACIU $3.16
- Resistance Level
- ACCD $3.80
- ACIU $3.41
- Average True Range (ATR)
- ACCD 0.18
- ACIU 0.24
- MACD
- ACCD 0.04
- ACIU 0.03
- Stochastic Oscillator
- ACCD 87.14
- ACIU 43.18
About ACCD Accolade Inc.
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.